Gabelli Funds LLC Has $8.10 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Gabelli Funds LLC boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 99.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 367,500 shares of the company's stock after purchasing an additional 183,000 shares during the quarter. Gabelli Funds LLC's holdings in Teva Pharmaceutical Industries were worth $8,100,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. FMR LLC increased its position in Teva Pharmaceutical Industries by 30.7% during the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after buying an additional 19,242,468 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after purchasing an additional 4,418,961 shares in the last quarter. Todd Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $58,243,000. Raymond James Financial Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $38,914,000. Finally, Norges Bank acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $38,550,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TEVA has been the topic of several analyst reports. StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday, April 14th. Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Finally, Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Down 2.9 %

Shares of Teva Pharmaceutical Industries stock traded down $0.39 during midday trading on Monday, hitting $13.26. The company's stock had a trading volume of 9,292,724 shares, compared to its average volume of 9,902,010. The firm has a market capitalization of $15.03 billion, a P/E ratio of -9.14, a PEG ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock has a 50-day simple moving average of $15.45 and a 200-day simple moving average of $17.67.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.